What biogenerics legislation does Hospira support in 2009?
Hospira supports a bipartisan bill in Congress, the “Promoting Innovation and Access to Life-Saving Medicine Act, (S.726/H.R. 1427),” that would create a legislative pathway allowing the FDA to approve safe and effective biogenerics to compete with existing biologic drugs. Competing bills in Congress also address biogenerics, but would prevent the drugs from reaching market as quickly. This legislation would establish a five-year exclusivity period for innovators’ biologic drugs, the same market exclusivity period given to small-molecule drugs under the 1984 Hatch-Waxman law. A five-year exclusivity period would both encourage innovator companies to research and develop new biologics, and allow generic competition to ease prices.
